A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Active, not recruiting
Peloton Therapeutics, Inc.
Phase 1
2016-12-07
The primary objective of this study is to identify the maximum tolerated dose (MTD) of
belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in
patients with advanced solid tumors
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Active, not recruiting
Peloton Therapeutics, Inc.
Phase 2
2018-05-02
This study is designed to investigate belzutifan as a treatment for VHL disease associated
RCC.
A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets
Completed
Peloton Therapeutics, Inc.
Phase 1
2018-02-23
This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16)
who are in general good health and selected for participation in the study according to the
selection criteria. This study will assess the effect of food on the pharmacokinetics of
belzutifan Tablets. The study will consist of two periods and will be conducted in a
crossover fashion.
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Recruiting
Peloton Therapeutics, Inc.
Phase 2
2018-09-27
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan
in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and
cabozantinib will be administered orally once daily.
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Recruiting
Merck Sharp & Dohme Corp.
Phase 3
2020-02-27
The primary objective of this study is to compare belzutifan to everolimus with respect to
progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare
everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is
superior to everolimus with respect to PFS and OS.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
